R-228060
R-228060 is in phase III clinical trials for the treatment of narcolepsy.
It was originally developed by SK Biopharmaceuticals. And Jazz Pharmaceuticals finally acquired the compound in 2014.
General Information
Update Date：2016-02-02
- Drug Name：
- R-228060
- Research Code：
- JZP-110; ADX-N05; ARL-N05; R-228060; SKL-N05; YKP-10A
- Trade Name：
- MOA：
- Unknown
- Indication：
- Narcolepsy
- Status：
- Phase III (Active)
- Company：
- SK (Originator) , Jazz Pharmaceuticals
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-22
|
Molecular Weight | 230.69 | ||||||||||||
| Formula | C10H14N2O2 ● HCl | |||||||||||||
| CAS No. |
178429-62-4; 561069-23-6; |
|||||||||||||
| Chemical Name | Benzenepropanol, b-amino-, 1-carbamate, (bR)-，hydrochloride (1:1) | |||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2016-01-05
1. WO9607637A1.
1. US2005080268A1.